AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01328938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCPGC 6mg
Description: Experimental: Stage II
Study NCT03460678 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pemetrexed
Description: Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium) administered as 500mg/m2 IV over 10 minutes on the first day of each 21-day cycle, until disease progression or unacceptable toxic effects
Study NCT03460678 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Description: Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride) administered once daily until disease progression or unacceptable toxic effects
Study NCT02291978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2100
Description: The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.
Study NCT02614638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One month of department-wide observation
Description: A pharmacy technician will be present full time in the care unit from Monday to Friday between 8:30 and 17h for 1 month for observational purposes only. During this phase, the pharmacy technician observes the current practices of preparation and administration of medication by nurses. He / she will collect medication errors and other observational data.
Study NCT02614638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharm Tech participates in department
Description: Following a 1 month wash-out period, a pharmacy technician will again be present full time (in practice, two technicians will relay each other) in the care unit from Monday to Friday between 8:30 and 17h for 1 month. He/she will actively take part in drug care activities in the department: management of product pathways, verification of injectable preparation, advice, etc. Medication errors and other observational data will be collected.
Study NCT01172873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: 50 mg dose of D-cycloserine administered at the end of each session of Cognitive Behavioral Therapy With Exposure and Response Prevention: twice weekly CBT/ERP of 60 minutes
Study NCT01172873 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and Response Prevention (EX/RP)
Description: Exposure and response prevention treatment. Participants complete graded exposure during twice weekly treatment sessions with therapist
Study NCT01711112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Treatment will be continued until progression, unacceptable toxicity, or refusal
Study NCT01268163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: European Taxotere®
Description: 60-100 mg/m\^2 IV
Study NCT01268163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: American Taxotere®
Description: 60-100 mg/m\^2 IV
Study NCT01268163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hospira Docetaxel Injection
Description: 60-100 mg/m\^2 IV
Study NCT01670370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-GemOx
Description: Rituximab Gemcitabine Oxaliplatin
Study NCT02039258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC
Description: Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg
Study NCT04144192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 1.8%
Study NCT04144192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch
Study NCT04144192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution
Study NCT03776448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sativa Nigra oil Softgels
Description: Nigella sativa, a flowering plant native to southwest Asia, is considered one of the most important healing medicinal plants in Islamic culture. The use of its richly colored black seeds has been recommended in the prophetic medicine. It's also known by various other names amongst different cultures. Importantly, its seed is known in Arabic as 'habat al Baraka' which translates literally to 'the seed of blessing'.The active ingredient is believed to be thymoquinone richly present in the oil extract of its seeds. Apart from mild occasional gastrointestinal disturbance, black seed oil has no side effects and is considered very safe. .
Study NCT03776448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Activated Charcoal Softgels
Description: This supplement is manufactured by \[Arkopharma Pharmaceutical Laboratories\] and is available commercially. The use of activated charcoal softgels as a placebo is documented in several other clinical trials. The single most relevant characteristic of charcoal is its minimal if any gastrointestinal absorption. As a result, it does not undergo any metabolism and is excreted completely in feces. This makes charcoal an attractive placebo choice for small trials or when manufacturing a specific placebo is not feasible. Charcoal softgels are black in color and resemble black seed oil softgels to a great extent.
Study NCT02756702 — intervention group
Intervention type: DEVICE
Intervention: All-Poly
Description: Implantation of the VEGA PS using all-polyethylene tibia components
Study NCT04873089 — intervention group
Intervention type: OTHER
Intervention: Cosmetic product
Description: It is a comparative study with two parallel groups of subjects:~* Tested group: twice daily application of the cream RV3278A cosmetic product on the whole face~* Comparative group: no application of study product or reference product
Study NCT01768663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Description: tablet, 200mg taken every 12 hours
Study NCT01768663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: tablet, 250mg taken every 12 hours
Study NCT01768663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 750 mg taken every 12 hours
Study NCT01768663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200mg taken once daily
Study NCT01768663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600mg taken once daily
Study NCT03312816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cookies enriched with POP
Description: Cookies
Study NCT02503852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celution System
Description: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
Study NCT02503852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kerastem Therapy
Description: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
Study NCT02503852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.
Study NCT02503852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liposuction
Description: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.
Study NCT02503852 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Liposuction
Description: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.
Study NCT00110877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/rtv
Description: One 400mg LPV tablet twice daily with 100mg RTV
Study NCT00110877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114/rtv
Description: Two 300mg TMC114 tablets twice daily with 100mg RTV
Study NCT00488475 — intervention group
Intervention type: DRUG
Intervention: etanercept
Description: The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study NCT02752698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro Hand S robotic surgery
Description: 20-70 patients undergo Micro Hand S robotic surgeries
Study NCT02752698 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic surgery
Description: 20-70 patients undergo laparoscopic surgeries
Study NCT02752698 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: da Vinci robotic surgery
Description: 20-70 patients undergo da Vinci robotic surgeries
Study NCT01133782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Access to diagnostic test
Description: Randomization to receive a result of diagostic procedure the following day.
Study NCT04695184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ICG-NIRF Imaging
Description: intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3)
Study NCT01867333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM
Description: A recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.
Study NCT01867333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM
Description: A recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.
Study NCT01867333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: An androgen receptor inhibitor.
Study NCT03390582 — intervention group
Intervention type: DRUG
Intervention: Methimazole Pill
Description: Hyperthyroidism patients are treated with Methimazole Pill according to the guidelines
Study NCT04253873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib mesylate (0-14 days, 500 mg, qd), taken half an hour after a meal (the daily dose should be as much as possible), one week apart, and then given temozolomide (150mg/m2 for 5 Days); every 28 days is a cycle, medication to disease progression, intolerable toxicity, etc.
Study NCT03803124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: 1 tablet before renography
Study NCT03803124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet before renography
Study NCT04242043 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: intel@med-feasibility
Description: Initial evaluation by the Nurse using the AI tool which enters into MEDVIR the patient's symptoms or functional complaints and comorbidities and is complemented by a telemedicine solution for data transmission to the remote tele-expert physician located in a regulatory center or health center. The remote doctor (a geriatrician from Prevention Care for Elderly Unit (UPSAV) platform of the Clinical Gerontology Division of the Limoges University Hospital) analyses the data collected by the Nurse and establishes a symptom severity criterion and a diagnosis with the help of the AI technology.~Both the geriatrician and the NHs nurse are not aware of the proposals made by AI.~The geriatrician can nevertheless initiate a visit to the resident's place of residence in order to verify the information necessary to establish the diagnosis and thus improve the relevance of the algorithm. For the resident, this study doesn't interfere with the usual care.
Study NCT01416389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously as a one hour infusion
Study NCT01416389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ixabepilone
Description: Administered intravenously
Study NCT01416389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Administered intravenously
Study NCT01416389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Administered intravenously
Study NCT04853641 — intervention group
Intervention type: PROCEDURE
Intervention: Cadaveric
Description: Cadaveric Organ Transplant
Study NCT04853641 — intervention group
Intervention type: PROCEDURE
Intervention: Living Donor
Description: Living Donor Organ Transplant
Study NCT04629573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumber Epidural
Description: Epidural procedure was performed by attending anesthesiologists who had completed at least 50 epidural procedures during their training. Patient was placed in the sitting position, the skin over the lumbar area was cleaned and a sterile technique was observed throughout the procedure. Skin and subcutaneous tissue were infiltrated with 1% lidocaine 2 mL at the intended site of epidural placement (L2-3 or L3-4 interspace). The lumbar epidural space was then located, using a midline approach with an 18 gauge Tuohy epidural needle via a loss of resistance technique with 2 mL of saline, 20 gauge epidural catheter was placed in each patient. We deliver an initial bolus of 20 ml bupivacaine 0.5% plus 100 mcg Fentanyl, followed by continuous infusion of bupivacaine 0.5% plus 1mcg/ml Fentanyl (3-5 ml/hr.).
Study NCT04629573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Anesthesia was initiated with IV fentanyl 1 µg/kg, propofol 2 mg/kg and cisatracurium 0.15 mg/kg to facilitate endotracheal intubation. After tracheal intubation, anesthesia was maintained with sevoflurane in O2 and air (FiO2 of 0.5), cisatracurium 1µg/kg/min and fentanyl 0.5 µg/ kg /h were infused. Volume-Controlled ventilation was performed in all patients. Cisatracurium and fentanyl infusion was stopped at the end of surgery, neuromuscular blockade was reversed, and the patient was extubated and send to post-anesthesia care unit.
Study NCT03659864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diesel exhaust particulate
Description: aerosolised diesel exhaust particulate
Study NCT03659864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carbon nanoparticles
Description: aerosolised 'clean' carbon nanoparticles
Study NCT03659864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: small graphene oxide
Description: aerosolised 'small' graphene oxide
Study NCT03659864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasmall graphene oxide
Description: aerosolised 'ultrasmall' graphene oxide
Study NCT03659864 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: filtered air
Description: control: filtered air
Study NCT02915484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: TDCS involves sending a weak electrical current to the brain to modulate brain functions.
Study NCT00862719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 600 mg sitagliptin taken orally per the schedule listed in each of the three separate arms.
Study NCT01228253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS: repetitive transcranial magnetic stimulation
Description: patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day)
Study NCT01228253 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM rTMS: repetitive transcranial magnetic stimulation is off
Description: patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day with the stimulator on off
Study NCT02436434 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA)
Description: Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
Study NCT02436434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA)
Description: Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
Study NCT03187964 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PLHIV Point of Care Xpert Ultra
Description: Sputum-based TB diagnostic test that takes 80 min to run. Test performed on the same day as the patient visit.
Study NCT03187964 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PLHIV Point of Care Xpert VL
Description: Blood-based HIV-1 VL diagnostic and monitoring test that takes 60 min to run. Test performed on the same day as the patient visit.
Study NCT00798590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon-Like Peptide-1
Description: 5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.
Study NCT00798590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.
Study NCT00324116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaptanib sodium (Macugen)
Description: 0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks.
Study NCT03878277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Starbucks® Cold brew - 325ml bottle
Description: Starbucks® Cold brew 325ml bottles daily \[205mg caffeine\] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit
Study NCT00357331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: potassium citrate
Description: 20 meq by mouth in capsule form twice daily
Study NCT00357331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: potassium citrate
Description: 20 meq by mouth in capsule form twice daily
Study NCT03245151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension
Study NCT03245151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 2 mg, 3 mg, or 5 mg tablets for oral suspension
Study NCT00469690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acular, Xibrom
Description: 1. Acular 5ml (in the eye)Instill one drop into the eye to be operated on four times a day at (6am, 12pm, 6pm, 12am)~2. Xibrom 5ml (in the eye) Instill one drop into the eye to be operated on two times a day (8am and 8pm)
Study NCT03117829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: Diet and Exercise Study to Improve Brain Blood Flow
Study NCT03312816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cookies enriched with POP
Description: Cookies
Study NCT01917279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel plus Capecitabine
Description: Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.~For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase.
Study NCT04385381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URECA CTO device
Description: facilitating guidewire re-entry into the true lumen after passing occlusion(s) in the peripheral vasculature with the URECA CTO device.
Study NCT01917279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Capecitabine
Description: Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.~For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase.
Study NCT01917279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Capecitabine
Description: Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle
Study NCT01917279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic Capecitabine
Description: Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
Study NCT06284499 — intervention group
Intervention type: OTHER
Intervention: measuring tooth stability after orthodontic treatment using a Periotest® device.
Description: The tooth mobility was determined by taking three repeat measurements from each tooth and calculating the average of these measurements, using a Periotest® device.
Study NCT00599703 — intervention group
Intervention type: OTHER
Intervention: fMRI Scan, pre- and post language evaluation
Description: All subjects will undergo functional MR imaging, pre- and post-surgical language evaluation, and electrocortical stimulation mapping. The brain tumor patients will undergo these procedures twice.
Study NCT04573088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCEPTANCE-BASED INTERVENTION
Description: 24 hours prior to surgery the patients undergo acceptance-based intervention, incorporating questions about their subjective perception about the surgery, the domains of their lives that have been affected, and on their own expectations from surgery and its effects on their lives. They will be asked to express their fears and worries about their condition and they will be discussed about the likelihood of experiencing postoperative pain.